Drug Trial Radar · NCT05458297
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
189
Planned (sponsor's estimate)
Start
Jul 21, 2022
Primary completion
May 17, 2029
Study completion May 17, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell therapy or ineligible for CAR-T cell therapy * Cohort B: Participants with relapsed or refractory RT disease after at least 1 prior systemic therapy * Cohort C: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 1 prior systemic therapy and no prior exposure to a non-covalent BTKi * Cohort D: Participants with relapsed or refractory FL and CLL relapsed or refractory disease after at least 2 prior systemic therapies and have no other available therapy * Cohort E: Participants with relapsed or refractory FL after at least 2 prior systemic therapies and have no other available therapy The primary study hypothesis is that zilovertamab vedotin monotherapy has an increased Objective Response Rate (ORR) per Lugano Response Criteria as assessed by blinded independent central review (BICR). As of Amendment 07, Cohort D is closed to enrollment of participants with CLL and enrollment of participants into Arm 2 (zilovertamab vedotin at Dose 2 on Days 1 \& 8 of each 3 Week Cycle (Q2/3W)). As of Amendment 09, no additional participants with RT will be enrolled in Cohort B; however, those currently enrolled will continue with study intervention treatment (if applicable) until a protocol specified discontinuation criterion is met. Cohort E will be closed, as no participants with FL have been treated in this cohort.
Conditions
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Richter Transformation Lymphoma
Interventions
Zilovertamab vedotinBiological
IV infusion
NemtabrutinibDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with MCL (Cohort C), FL (Cohort D), and CLL (Cohort D) with ≥1 Adverse Event (AE)Time frame: Up to approximately 81 months
- Percentage of Participants with MCL (Cohort C), FL (Cohort D), and CLL (Cohort D) who Discontinue from Study Therapy Due to AETime frame: Up to approximately 81 months
- Percentage of Participants with MCL (Cohort C) who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 81 months
- Objective Response Rate (ORR) per Lugano Response Criteria as Assessed by Blinded Independent Central Review (BICR) in Participants with MCL (Cohort A), RT (Cohort B), and FL (Cohort D)Time frame: Up to approximately 81 months
- ORR per Lugano Response Criteria as Assessed by Investigator in Participants with MCL (Cohort C)Time frame: Up to approximately 81 months
- ORR per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Investigator in Participants with CLL (Cohort D)Time frame: Up to approximately 81 months
Locations
109 sites in 21 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology ( Site 0037)
Anchorage, Alaska
Banner MD Anderson Cancer Center ( Site 0040)
Gilbert, Arizona
Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036)
Phoenix, Arizona
University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008)
Aurora, Colorado
Cancer Care Specialists of Illinois ( Site 0031)
Decatur, Illinois
University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics ( Site 0038)
Fairway, Kansas
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007)
Saint Matthews, Kentucky
Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010)
Baltimore, Maryland
Tufts Medical Center ( Site 0024)
Boston, Massachusetts
Massachusetts General Hospital ( Site 0018)
Boston, Massachusetts
Dana-Farber Cancer Institute-Lymphoma ( Site 0026)
Boston, Massachusetts
University of Michigan ( Site 0009)
Ann Arbor, Michigan
Henry Ford Hospital ( Site 0035)
Detroit, Michigan
Icahn School of Medicine at Mount Sinai ( Site 0023)
New York, New York
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014)
Fargo, North Dakota
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0004)
Columbus, Ohio
Avera Cancer Institute- Research ( Site 0011)
Sioux Falls, South Dakota
Medical Oncology Associates, PS ( Site 0005)
Spokane, Washington
University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030)
Madison, Wisconsin
Medical College of Wisconsin ( Site 0021)
Milwaukee, Wisconsin
Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1809)
Rio de Janeiro, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808)
São Paulo, Brazil
Hospital Paulistano-Americas Oncologia ( Site 1805)
São Paulo, Brazil
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807)
Natal, Rio Grande do Norte, Brazil
BC Cancer Vancouver-Clinical Trials Unit ( Site 0201)
Vancouver, British Columbia, Canada
The Moncton Hospital-Oncology ( Site 0211)
Moncton, New Brunswick, Canada
QEII Health Sciences Centre - Victoria General Site ( Site 0213)
Halifax, Nova Scotia, Canada
London Health Sciences Centre ( Site 0203)
London, Ontario, Canada
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200)
Toronto, Ontario, Canada
Jewish General Hospital ( Site 0202)
Montreal, Quebec, Canada
Allan Blair Cancer Centre-Care Services ( Site 0208)
Regina, Saskatchewan, Canada
IC La Serena Research ( Site 1909)
La Serena, Coquimbo Region, Chile
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907)
Santiago, Region M. de Santiago, Chile
Clínica Inmunocel ( Site 1910)
Santiago, Region M. de Santiago, Chile
Clínica Alemana de Santiago ( Site 1903)
Santiago, Region M. de Santiago, Chile
Beijing Cancer hospital ( Site 1200)
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center ( Site 1201)
Guangzhou, Guangdong, China
Zhujiang Hospital ( Site 1207)
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital ( Site 1202)
Guangzhou, Guangdong, China
Henan Cancer Hospital-hematology department ( Site 1212)
Zhengzhou, Henan, China
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.